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Short Communication
Chromosome instability and benefit from adjuvant anthracyclines
in breast cancer
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2University of Leeds and Cancer Research UK Centre, St James’ University Hospital, Leeds LS2 9JT, UK; 3Edinburgh Cancer Centre, Western General
Hospital, Crewe Road South, Edinburgh EH4 2XU, UK; 4Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower,
101 College Street, Suite 800, Toronto, Ontario, Canada M5G 0A3
BACKGROUND: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An
explanation may be chromosome instability (CIN); a frequent event in solid tumours associated with poor outcome. The predictive
value of CIN seems to be drug dependent and CIN has been associated with both sensitivity and resistance to chemotherapy.
METHODS: In this study, we used fluorescent in situ hybridisation for chromosomes 1, 7, 11, 17 and 18 to identify patients with high
tumour CIN% in 322 patients recruited into the BR9601 clinical trial.
RESULTS: High tumour CIN% was correlated to Ch17CEP (P¼ 3.68e 7) and is associated with a reduced RFS (P¼ 0.0011) and
OS (P¼ 0.04). Patients with high CIN had a decreased risk of death on E-CMF compared with CMF.
CONCLUSION: CIN is of prognostic significance and may be of predictive value in determining anthracycline response, although
further testing is required.
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Chromosome instability (CIN) is a frequent characteristic of solid
tumours and is characterised by gain or loss of whole or partial
chromosomes. Patients whose tumours have CIN have a poor
prognosis across many cancer types including breast and colon
cancer (Carter et al, 2006; Walther et al, 2008; Smid et al, 2010).
Chromosome instability is more prevalent in ER-negative disease,
basal and triple-negative breast tumours (Smid et al, 2010).
We recently demonstrated that duplication of the centromeric
region of chromosome 17 (Ch17CEP duplication), one of several
chromosomes utilised to assess CIN (Takami et al, 2001; Miyoshi
et al, 2002), is a predictive marker of sensitivity to anthracycline-
containing chemotherapy in a meta-analysis of NEAT, BR9601 and
MA.5 clinical trials (Bartlett et al, 2009, 2010). Initial analysis of the
NEAT, BR9601 and MA.5 studies assessed the predictive role of
HER2 amplification on outcome in patients treated with anthracy-
cline-containing polychemotherapy compared with CMF gave
conflicting results (Pritchard et al, 2006; Bartlett et al, 2008,
2010; Munro et al, 2010). Ch17CEP duplication is the only pre-
dictive marker of anthracycline response providing consistent
results across all trials (Bartlett et al, 2009). Duplication of
Ch17CEP, however, does not immediately identify a functional link
to a specific gene pathway. The chromosome enumeration
probe (CEP) binds a non-coding pericentromeric a-satellite repeat
on chromosome 17 that can both enumerate chromosome
copy number and identify amplification of this region within
the chromosome (without chromosome duplication) (Marchio
et al, 2009).
In this study, we assessed CEPs for chromosomes 1, 7, 11 and 18
by fluorescent in situ hybridisation (FISH) to confirm whether
Ch17CEP duplication is a surrogate marker of CIN in the context
of anthracycline response. This, together with data previously
collected for chromosome 17, was used to assess whether CIN
is a potential predictive marker of anthracycline response in the
BR9601 clinical trial.
PATIENTS AND METHODS
Patients
The BR9601 study recruited 374 pre- and post-menopausal women
with completely excised, histologically confirmed breast cancer who
had a clear indication for adjuvant chemotherapy. Patients were
randomised between the standard arm of eight cycles of CMF (i.v.
cyclophosphamide 750mgm 2, methotrexate 50mgm 2 and
5-fluorouracil 600mgm 2) given every 21 days and E-CMF (four
cycles of epirubicin 100mgm 2 every 21 days followed by four
cycles of the same CMF regimen) (Poole et al, 2006); their
characteristics are shown in Table 1. The protocol was approved
by central and local ethics committees, and each patient provided
written informed consent before randomisation. The primary
outcomes of the BR9601 study were RFS and OS, and results were
published in a joint analysis with the NEAT trial (Poole et al, 2006).
For the current analysis, following approval by central ethics
committee, tissue blocks were retrieved from 322 cases (85.8%).
Triplicate tissue microarrays (TMAs) were constructed following
review by a pathologist (JST) according to current guidelines
(Leyland-Jones et al, 2008).
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Fluorescent in situ hybridisation
Fluorescent in situ hybridisation was performed using centromeric
probes for chromosomes 1, 7, 11 and 18 (Abbott Molecular,
Maidenhead, UK), as previously described (Ellis et al, 2000;
Bartlett et al, 2001). Chromosomes 1 and 11 were labelled with
SpectrumOrange whereas chromosomes 7 and 18 were labelled with
SpectrumGreen allowing dual colour FISH to be performed with
chromosomes 1 and 7, and 11 and 18. Results for chromosome 17
were available from a previous analysis using the triple-colour
probe for HER2/TOP2A/CHR17 (Bartlett et al, 2008). Centromeric
duplication (CEP duplication) was defined as a chromosome CEP
copy number 41.86, as previously defined for chromosome 17
(Watters et al, 2003; Bartlett et al, 2010).
Defining chromosome instability
Signals for each chromosome were counted in intact non-
overlapping nuclei. In total, 20–40 nuclei were counted in each
tumour sample for chromosomes 1, 7, 11 and 18 (Watters et al,
2003) with 93–99% of samples having results for at least 20 nuclei
for each chromosome. The percentage CIN for each tumour was
defined by first calculating the percentage of nuclei with a CEP
signal number different to the modal number for each individual
chromosome (CIN % by chromosome¼ chromosome CIN%), and
then calculating the mean CIN percentage of all chromosomes
analysed (CIN % by tumour¼ tumour CIN%), as defined by
Lengauer et al (1997). High tumour CIN% was defined as a mean
tumour CIN percentage higher than the upper quartile; all other
tumours were classed as having low tumour CIN%.
Statistics
The SPSS (v14; SPSS Inc., Chicago, IL, USA) statistical package was
used for statistical analysis. Kaplan–Meier estimates of survival
were used for analysis of relapse-free and overall survival. The Cox’s
proportional hazard model was used to obtain hazard ratios for
relapse or death. When comparing outcomes between the treatment
arms within the two groups of patients identified by bio-marker
expression; P-values were not calculated for sub-groups to avoid
multiple testing and bias, where one group was much smaller than
the other. The Cox model was instead used to identify statistically
significant interactions (Po0.05) between chromosomal alterations
and outcome on the different treatments (treatment by marker
effect), in models that also included chromosome status (marker
effect) and treatment, as covariates.
RESULTS
Correlation of CIN and clinicopathological parameters
Analysis of chromosomes 1, 7, 11, 17 and 18 was successful in
72.9%, 72.9%, 82.6%, 93.8% and 82.6% of cases, respectively.
Fluorescent in situ hybridisation analysis of chromosome 17 was
performed for an earlier study; therefore, the percentage of
successfully analysed cases was lower for chromosomes 1, 7,
11 and 18 owing to a loss of cores on the TMAs. The percentage
CIN for individual chromosomes (Table 2) was used to calculate
the mean tumour CIN% for 86.3% (278) of tumour samples with
the tumour CIN% ranging from 26.8% to 64.0% (median
interquartile range: 40.0–47.3%). Tumours with over 47.3% CIN
(above the upper quartile) were defined as having high tumour
CIN% with all other tumours being classed as having low tumour
CIN%. High tumour CIN% was correlated (Pearson’s w2) with high
pathological grade (P¼ 0.008), HER2 amplification (P¼ 2.89e-5),
and Ch17CEP duplication (P¼ 3.68e-7) but was not associated
with size, nodal status, ER or proliferation (measured by Ki67;
Supplementary Table S1).
Tumour CIN% as a marker for RFS and OS
The prognostic significance of tumour CIN% in this study was first
tested on the entire patient cohort, irrespective of allocated
adjuvant chemotherapy. High tumour CIN% was associated with a
markedly reduced RFS (Figure 1A; P¼ 0.0011) and OS (Figure 1B;
P¼ 0.04). In univariate analysis, patients with a high tumour
CIN% had a 1.58-fold (95% CI: 1.02–2.46) increased risk of dying
from breast cancer and 2.13-fold (95% CI: 1.34–4.56) increased risk
of relapse when compared with those with a low tumour CIN%. In
multivariate analysis, high tumour CIN% was not an independent
predictor for RFS (HR: 1.28, 95% CI: 0.74–2.209) but for OS there
was a strong trend that did not reach statistical significance (HR:
1.76, 95% CI: 0.99–3.13, P¼ 0.054).
Tumour CIN% as a biological marker for anthracycline
therapy
In univariate analysis, patients with high tumour CIN% had a
decreased risk of death (HR: 0.39, 95% CI: 0.17–0.92) and a trend
Table 1 Patient characteristics from the BR9601 trial
BR9601 TMA
Number 374 322
Age (years) 50.6 (22.7–76.0) 50.6 (26.2–76.0)
E-CMF 183 (48.9%) 158 (49.1%)
CMF 191 (51.1%) 164 (50.9%)
Size
o2.0 cm 123 (32.9%) 105 (32.7%)
2.0–5.0 cm 226 (60.4%) 197 (61.1%)
45.0 cm 25 (6.7%) 20 (6.2%)
Nodes
0 48 (12.8%) 44 (13.6%)
1–3 214 (57.3%) 180 (56.0%)
X4 112 (29.9%) 98 (30.4%)
Grade
1 22 (5.9%) 22 (6.9%)
2 126 (33.7%) 109 (30.4%)
3 210 (56.1%) 189 (58.6%)
Unknown 16 (4.2%) 2 (0.6%)
NPI 5.30 (4.50–5.61) 5.30 (4.50–5.60)
ER status
Positive 202 (62.9%) 176 (62.6%)
Negative 119 (37.1%) 105 (37.4%)
Unknown 53 40
Abbreviations: CMF¼ cyclophosphamide, methotrexate and 5-fluorouracil; E-CMF¼
epirubicin CMF; ER¼ oestrogen receptor; NPI¼Nottingham Prognostic Index;
TMA¼ tissue microarray.
Table 2 Average and median CIN for individual chromosomes
Chromosome
Average
chromosomal
CIN (%)
Median CIN
(interquartile
range) (%)
CIN1 43.6 45.0 (36.0–50.0)
CIN7 43.6 45.0 (37.5–50.0)
CIN11 42.3 43.8 (37.5–47.5)
CIN17 45.8 46.7 (40.0–52.1)
CIN18 42.0 44.4 (35.7–48.4)
Abbreviation: CIN¼ chromosome instability.
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towards a decreased risk of relapse (HR: 0.46, 95% CI: 0.20–1.05)
when treated with E-CMF compared with CMF alone (Figure 2A
and B). No apparent benefit of E-CMF vs CMF was noted in
patients with low tumour CIN% for either RFS or OS. In a
multivariate analysis with adjustment for size, nodal status, ER,
pathological grade, HER2, Ch17CEP duplication, Ki67, Ch17CEP*-
TREAT (treatment by marker interaction for Ch17CEP and
treatment), tumour CIN%, TREAT (treatment) and tumour
CIN%*TREAT showed only nodal status (for RFS and OS), and
ER and high tumour CIN% (for OS but not RFS) to be statistically
significant. There was a trend for tumour CIN%*TREAT for OS
(HR: 0.31, 95% CI: 0.09–1.07, P¼ 0.063), however, no significant
association with RFS (HR: 0.55, 95% CI: 0.17–1.74, P¼ 0.305) was
apparent (Table 3).
Individual chromosome analysis
Exploratory analyses were conducted using the copy number data
for the individual chromosomes. Low Ch1CEP was associated with
a reduced OS (HR: 1.66, 95% CI: 1.02–2.70, P¼ 0.04) but not RFS
(HR: 1.29, 95% CI: 0.82–2.01). No association with RFS and OS was
noted for Ch7CEP, Ch11CEP, Ch17CEP or Ch18CEP (P40.05).
Subsequent exploratory analyses assessed the effect of individual
CEP duplication on RFS and OS between patients treated with
E-CMF and those treated with CMF alone (Supplementary Table S2
and Supplementary Figure 1A and B). In a multivariate analysis
and adjustment for size, nodal status, ER, pathological grade,
HER2, Ch17CEP, Ki67, Ch17CEP*TREAT, Ch7CEP, TREAT and
Ch7CEP*TREAT, the hazard ratio for the Ch7CEP treatment
marker effect is 0.27 (95% CI: 0.08–0.96, P¼ 0.042) for OS and 0.23
(95% CI: 0.07–0.75, P¼ 0.015) for RFS (Supplementary Table S3).
DISCUSSION
In this study, we investigated the role of tumour CIN% in breast
carcinomas recruited into the BR9601 trial. We have shown high
tumour CIN% to be correlated to Ch17CEP duplication suggesting
that Ch17CEP could be acting as a surrogate marker for CIN,
therefore giving a more mechanistic/functional explanation to
previous results (Bartlett et al, 2009). Furthermore, we have
demonstrated high tumour CIN% to be a potential prognostic
marker for OS and RFS in this cohort of breast cancer patients.
This supports previous studies that have shown CIN to be
associated with a poor prognosis in a number of solid tumours
including breast cancer (Carter et al, 2006). Carter et al (2006)
characterised CIN using a CIN70 gene signature containing genes
known to be involved in processes such as chromosome segregation,
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Figure 1 Relapse-free and overall survival for high tumour CIN- (dashed
lines) vs low tumour CIN- (solid lines)treated cases. (A) Relapse-free
survival. (B) Overall survival.
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Figure 2 Overall survival for E-CMF- (solid lines) vs CMF- (dashed
lines)treated cases. (A) Low tumour CIN% cases (see text). (B) High
tumour CIN% cases (see text).
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cell cycle checkpoints and DNA replication. Assessment of CIN70 in
the OV01 ovarian cancer clinical trial showed increased expression
of CIN genes to be associated with both resistance to taxanes and
sensitivity to carboplatin suggesting the predictive value of CIN
may be drug dependent (Swanton et al, 2009). In this study, we
have shown a trend towards significance for an increased benefit
from the addition of anthracycline in patients with high CIN. The
small number of patients in the high CIN group meant the test was
statistically underpowered and therefore should be regarded as
hypothesis generating and tested on a larger cohort of patients.
Exploratory analysis of the individual chromosomes highlighted
Ch7CEP as another candidate marker of response to anthracyclines.
In patients with low Ch7CEP, there is a 62.6% reduction in the risk
of death when treated with anthracyclines compared with CMF.
The association between low levels of Ch7CEP and response to
anthracyclines is interesting; however, this study is underpowered
and this would require testing in a large cohort.
Our findings demonstrate that Ch17CEP is associated with CIN.
High tumour CIN% is of prognostic value and may be able to
predict response to anthracycline-based therapy, although testing
in a larger cohort would be required to confirm this.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Bartlett JM, Desmedt C, Munro A, O’Malley FP, Larsimont D, Di Leo A,
Cameron DA, Isola J, Shepherd L, Twelves CJ, Pritchard KI. for the HER
(2009) Chromosome 17 polysomy: a unifying hypothesis underlying
benefit from adjuvant anthracyclines? Cancer Res 69: 6059
Bartlett JMS, Going JJ, Mallon E, Watters AD, Reeves JR, Stanton PD,
Richmond J, Donald B, Ferrier R, Cooke TG (2001) Evaluating HER2
amplification and overexpression in breast cancer. J Pathol 195: 422–428
Bartlett JMS, Munro AF, Cameron DA, Thomas JS, Prescott RJ, Twelves C
(2008) Type I receptor tyrosine kinase profiles identify patients with
enhanced benefit from anthracyclines in the BR9601 adjuvant breast
cancer chemotherapy trial. J Clin Oncol 26: 1–9
Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ,
Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C,
Pharoah P, Hiller L, Earl H, Poole CJ (2010) Predictive markers of
anthracycline benefit: a prospectively planned analysis of the UK
National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11:
266–274
Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature
of chromosomal instability inferred from gene expression profiles
predicts clinical outcome in multiple human cancers. Nat Genet 38:
1043–1048
Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B,
Mallon E, Barrett Lee P (2000) Recommendations for HER2 testing in the
UK. J Clin Pathol 53: 890–892
Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in
colorectal cancers. Nature 386: 623–627
Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJC, Enos RA, Raji A,
Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S,
Cardoso F, Harbeck N, Denkert C, Jewell SD (2008) Recommendations
for collection and handling of specimens from group breast cancer
clinical trials. J Clin Oncol 26: 5638–5644
Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B,
Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-
Filho JS, Sapino A (2009) Does chromosome 17 centromere copy number
predict polysomy in breast cancer? A fluorescence in situ hybridization
and microarray-based CGH analysis. J Pathol 219: 16–24
Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S (2002) Acceleration of
chromosomal instability of BRCA1-associated hereditary breast cancers
by p53 abnormality. Breast J 8: 77–80
Munro AF, Cameron DA, Bartlett JMS (2010) Targeting anthracyclines in
early breast cancer: new candidate predictive biomarkers emerge.
Oncogene 29: 5231–5240
Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA,
Agrawal RK, Fernando IN, Brunt AM, O’Reilly SM, Crawford SM, Rea
DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L,
Leonard RCF, Twelves CJ, The NEAT Investigators and the
SCTBG (2006) Epirubicin and cyclophosphamide, methotrexate, and
fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med
355: 1851–1862
Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH,
Levine MN, The National Cancer Institute of Canada Clinical Trials
Group (2006) HER2 and responsiveness of breast cancer to adjuvant
chemotherapy. N Engl J Med 354: 2103–2111
Smid M, Hoes M, Sieuwerts A, Sleijfer S, Zhang Y, Wang Y, Foekens J,
Martens J (2010) Patterns and incidence of chromosomal instability and
their prognostic relevance in breast cancer subtypes. Breast Cancer Res
Treat 128: 23–30
Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee
A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG,
Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z,
Downward J (2009) Chromosomal instability determines taxane
response. PNAS 106: 8671–8676
Takami S, Kawasome C, Kinoshita M, Koyama H, Noguchi S (2001)
Chromosomal instability detected by fluorescence in situ
hybridization in Japanese breast cancer patients. Clin Chim Acta 308:
127–131
Walther A, Houlston R, Tomlinson I (2008) Association between
chromosomal instability and prognosis in colorectal cancer: a meta-
analysis. Gut 57: 941–950
Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17
aneusomy is associated with poor prognostic factors in invasive breast
carcinoma. Breast Cancer Res Treat 77: 109–114
Table 3 Multivariate analysis of tumour CIN% and treatment interaction
OS P-value RFS P-value
TREAT 0.653 (0.294–1.448) 0.294 0.644 (0.322–1.285) 0.212
Size (420mm) 0.849 (0.465–1.549) 0.593 1.074 (0.618–1.869) 0.799
Nodal status (positive vs negative) 5.890 (1.756–19.757) 0.004 6.954 (2.082–23.225) 0.002
ER 0.461 (0.246–0.864) 0.016 0.653 (0.372–1.147) 0.138
Pathological grade (grade1/2 vs 3) 1.956 (0.920–4.160) 0.081 1.478 (0.786–2.780) 0.226
HER2 amplification 1.510 (0.838–2.722) 0.170 1.334 (0.773–2.301) 0.301
Ch17CEP 0.811 (0.355–1.855) 0.620 1.249 (0.609–2.562) 0.543
High Ki67 (413%) 0.860 (0.458–1.615) 0.638 1.053 (0.597–1.856) 0.859
High tumour CIN% 2.864 (1.334–6.151) 0.007 1.615 (0.792–3.292) 0.188
Ch17CEP*TREAT 1.618 (0.514–5.093) 0.410 1.021 (0.361–2.883) 0.969
Tumour CIN%*TREAT 0.308 (0.089–1.067) 0.063 0.545 (0.171–1.736) 0.305
Abbreviation: CIN%¼ percentage chromosome instability; ER¼ oestrogen receptor; OS¼ overall survival; RFS¼ relapse-free survival; TREAT¼ treatment.
Chromosome instability, a predictive marker of anthracycline benefit
AF Munro et al
74
British Journal of Cancer (2012), 107(1), 71 – 74 & 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
